The Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Varubi (rolapitant; Tesaro) for use in combination with other antiemetics in adults to prevent delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Varubi, a highly selective and competitive antagonist of human substance P/neurokinin (NK-1) receptor, is already available as 90mg strength tablets. Clinical data from a bioequivalence trial showed comparability of the oral and IV formulations of Varubi.
Varubi IV should be administered intravenously within 2 hours prior to the start of chemotherapy as a 30-minute infusion. Common infusion-related adverse events include sensation of warmth, abdominal pain, dizziness, and paresthesia.
Varubi IV will be available as a single-dose vial containing 166.5mg/92.5mL (1.8mg/mL) strength injectable emulsion. It is anticipated to launch in November 2017.
For more information call (844) 483-7276 or visit VarubiRx.com.